You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • P16 Implications of nice guidance in england and wales on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis

Article metrics

Article menu

Download PDFPDF

Asthma: airways and antibodies
P16 Implications of nice guidance in england and wales on eligibility for treatment with mepolizumab and omalizumab – an ideal study analysis
Free

 

Online download statistics by month:

Online download statistics by month: November 2017 to September 2024

AbstractFullPdf
Nov 20172405
Dec 20175006
Jan 20189804
Feb 20182202
Mar 20181805
Apr 20183801
May 20184003
Jun 20182200
Jul 20182203
Aug 20182603
Sep 20181404
Oct 20184604
Nov 20181602
Dec 20181402
Jan 20193002
Feb 20193004
Mar 20191405
Apr 20192805
May 2019601
Jun 20194104
Jul 20195609
Aug 20194802
Sep 20193202
Oct 20192406
Nov 20191003
Dec 20192200
Jan 20202603
Feb 20201000
Mar 2020203
Apr 20201400
May 2020601
Jul 20202103
Aug 2020501
Sep 20202201
Oct 20201602
Nov 20202602
Dec 20202403
Jan 20212204
Feb 20212705
Mar 20211203
Apr 20211000
May 2021507
Jun 2021003
Jul 2021005
Aug 2021103
Sep 20210010
Oct 202138017
Nov 20214013
Dec 2021605
Jan 20221607
Feb 20223203
Mar 20221601
Apr 20221802
May 20221507
Jun 20221003
Jul 20221201
Aug 20221302
Sep 2022203
Oct 20221204
Nov 2022805
Dec 20222000
Jan 2023604
Feb 2023200
Mar 20231001
Apr 2023200
May 2023201
Jun 2023001
Jul 2023603
Aug 2023201
Sep 20231501
Oct 2023201
Nov 2023901
Dec 2023200
Jan 2024600
Feb 2024601
Mar 20244012
Apr 20241001
May 2024802
Jun 2024500
Jul 2024704
Aug 2024404
Sep 20241001
Total13800258